| INGELHEIM, Germany & HOUSTON - Wednesday, December 2nd 2015 [ME NewsWire]
Pancreatic ductal adenocarcinoma is one of the most lethal of cancers with no effective treatments available
Boehringer Ingelheim and MD Anderson Cancer Center to identify new therapeutic concepts, biomarkers and develop breakthrough medicines to treat pancreatic cancer
This collaboration underscores Boehringer Ingelheim’s focus on difficult-to-treat diseases and commitment to precision medicines
(BUSINESS WIRE)-- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s experience in drug discovery and development.
Pancreatic cancer accounts for four percent of cancer deaths worldwide (330,000 people) and is the seventh most common cause of death from cancer. Pancreatic cancer is anticipated to become the second leading cause of cancer-related death in the United States before 2030. Newly diagnosed patients have a median survival of less than one year, and a 5-year survival rate of only 3 to 5 percent. PDAC is one of the most lethal of cancers due to its late detection and resistance to available standard-of-care therapy. Effective medicines directed against PDAC are therefore urgently needed.
“We are excited to be able to work with the leading cancer research and care institution in the world to develop therapies for patients with this devastating cancer,” said Clive Wood, senior corporate vice president of Discovery Research at Boehringer Ingelheim. “This partnership is a perfect match because it combines MD Anderson’s outstanding capabilities in preclinical concept validation and clinical testing with Boehringer Ingelheim’s strength in developing innovative medicines in novel target spaces.”
The collaboration will focus on identifying and developing therapeutic concepts in novel target areas as well as identification of biomarkers that can accurately identify patients who would respond to potential new therapies.
“At MD Anderson, we have created integrated platforms that will enable the discovery of more effective therapeutics for cancer patients,” said Timothy Heffernan, executive director and co-leader for MD Anderson’s Center for Co-Clinical Trials. “This alliance combines expertise in cancer genetics and translational medicine with outstanding drug discovery and development and it has great potential to conquer devastating diseases like pancreatic cancer.”
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/02_december_2015_collaboration.html
Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Corporate Communications
Phone: +49 (6132) 77-90815
E-Mail: press@boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/16522/en
|
